New hope for advanced breast cancer patients in early drug trial
NCT ID NCT07358377
Summary
This early-stage study is testing whether adding a new experimental drug called HRS-6209 to existing breast cancer medications (fulvestrant or letrozole) is safe and might help control advanced breast cancer. The trial will enroll 15 patients with hormone-positive, HER2-negative breast cancer that has spread or cannot be surgically removed. Researchers will monitor side effects closely and check if tumors shrink or stop growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.